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Intracellular trafficking of viruses can be influenced by a
variety of inter-connected cellular sorting and degradation
pathways involving endo-lysosomal vesicles, the ubiquitin-pro-
teasome system, and autophagy-based or endoplasmic reticu-
lum-associated machinery. In the case of recombinant adeno-
associated viruses (AAV), proteasome inhibitors are known to
prevent degradation of ubiquitinated AAV capsids, thereby
leading to increased nuclear accumulation and transduction.
However, the impact of other cellular degradation pathways on
AAV trafficking is not well understood. In the current study, we
screened a panel of small molecules focused on modulating dif-
ferent cellular degradation pathways and identified eeyarestatin
I (EerI) as a novel reagent that enhances AAV transduction. EerI
improved AAV transduction by an order of magnitude regard-
less of vector dose, genome architecture, cell type, or serotype.
This effect was preceded by sequestration of AAV within
enlarged vesicles thatwere dispersed throughout the cytoplasm.
Specifically, EerI treatment redirected AAV particles toward
large vesicles positive for late endosomal (Rab7) and lysosomal
(LAMP1) markers. Notably, MG132 and EerI (proteasomal
and endoplasmic reticulum-associated degradation inhibitors,
respectively) appear to enhance AAV transduction by increas-
ing the intracellular accumulationof viral particles in amutually
exclusive fashion. Taken together, our results expand on poten-
tial strategies to redirect recombinant AAV vectors toward
more productive trafficking pathways by deregulating cellular
degradation mechanisms.
Eukaryotic cells utilize tightly regulated pathways to sort and
degrade internalized cargo by exploiting lysosomal proteases,
the ubiquitin-proteasome system, and endoplasmic reticulum
(ER)3-associated or autophagy-based machinery. ER-associ-
ated degradation, or ERAD, is a critical eukaryotic process that
involves extraction and ubiquitination of misfolded proteins
followed by their degradation by the proteasomal machinery
(1). Several viral pathogens exploit this process to infect and
replicate within host cells (2, 3). For instance, polyomaviruses
appear to interactwith ER lumen components to rearrange cap-
sid proteins and subsequently retrotranslocate into the cytosol
(4). Another constitutive degradation pathway essential for
maintaining cellular homeostasis is autophagy (5). As with
ERAD, several viruses have now been shown to subvert or
mimic autophagy to facilitate replication and/or dissemination
(6–8). The specific degradation pathway and the subsequent
intracellular fate of viral proteins as well as their genomic cargo
within the host cell are often dictated by a variety of preceding
vesicular sorting events.
Recently, vesicular transport of non-enveloped parvoviruses
such as the minute virus of mice (MVM) through the ER and
Golgi has been shown to accelerate progeny virus release (9). A
particularly interesting member of the same parvovirus family
is the helper-dependent adeno-associated virus (AAV), which
replicates upon co-infection with adenoviruses or other viruses
such as herpes simplex virus or papillomavirus. This small,
non-pathogenic Dependoparvovirus contains a 4.7-kb ssDNA
genome packaged within an icosahedral capsid 25 nm in
diameter (10). Different AAV serotypes recognize various cell
surface glycans such as heparan sulfate, sialic acid, or galactose
as primary receptors for attachment (11). Subsequent internal-
ization of AAV particles into endocytic vesicles is thought to be
mediated by integrins and/or specific transmembrane recep-
tors. In addition, several diverse and cell-specific mechanisms
of endocytic uptake ranging from macropinocytosis to the
CLIC/GEEC (CLathrin-Independent Carriers, GPI-Enriched
Endocytic Compartment) pathway have been described (12,
13). Despite these differences, perinuclear accumulationwithin
the Golgi apparatus (14–18) and exploitation of the nuclear
import machinery for nuclear entry appear to be broadly con-
served, downstream trafficking events (19).
Although these studies provide a detailedmap of AAV trans-
port within the host cell, it remains unclear whether the mod-
ulation of cellular degradation pathways such as ERAD or
autophagy outlined earlier can influence AAV trafficking.Most
studies to date have focused on proteasome inhibitors such as
MG132 (20), Llnl (21), and bortezomib or carfilzomib (22, 23),
which have been shown to increase AAV transduction through
increased nuclear/nucleolar accumulation of viral particles. In
the current study,we tested the effect of several smallmolecules
that modulate the ubiquitin-proteasome system, autophagy,
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and/or ERAD on AAV transduction. The overall goal of the
study was to understand the interplay (or lack thereof) between
these different cellular degradation pathways in facilitating or
restricting AAV trafficking within host cells. In doing so, we
identified an ERAD inhibitor (eeyarestatin I/EerI) that deregu-
lates endocytic sorting of AAV particles and redirects viral
transport toward Rab7/Lamp1 vesicles prior to nuclear entry.
More importantly, we established an approach to facilitate
improved trafficking of AAV capsids to the nucleus through
mutually exclusive, yet synergistic approaches.
Materials andMethods
Cell Culture—HeLa, HepG2, and Huh7 cells were main-
tained in Dulbecco’s modified Eagle’s medium with 10% FBS,
100 units/ml penicillin, 100g/ml streptomycin, and 2.5g/ml
amphotericin B (Sigma-Aldrich). Human fibroblasts (AG05244)
were obtained fromCoriell Cell Repositories (Camden, NJ) and
were maintained in Dulbecco’s modified Eagle’s medium with
15% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin.
All cells were maintained at 37 °C and 5% CO2.
Antibodies, Chemicals, and Cell Labeling Reagents—Mouse
anti-VCP (ab11433), rabbit anti-VCP (ab109240), and mouse
anti-actin (ab3280) antibodies were obtained from Abcam
(Cambridge, MA). Rabbit anti-EEA1 (C45B10) and rabbit anti-
Golgin97 (D8P2K)were obtained fromCell Signaling (Danvers,
MA). Rabbit anti-STX5 (110053) was obtained from Synaptic
Systems (Goettingen, Germany). Goat anti-mouse-HRP anti-
body (32430) was obtained from Thermo Fisher. Anti-capsid
protein antibody B1 (24) was used to blot for capsid protein,
whereas anti-capsid antibody A20 (25) was used for immuno-
precipitation and immunostaining. EerI (E1286), PR-619
(SML0430), PYR-41 (N2915), 3-methyladenine (M9281), nica-
rdipine (N7510), and spautin-1 (SML0440) were obtained from
Sigma-Aldrich.MG132 (10012628)was obtained fromCayman
Chemical (Ann Arbor, MI). Bortezomib (S1013) was obtained
from Selleck Chemicals (Houston, TX). BacMam 2.0 baculovi-
rus delivering EmeraldGreenGFP (emGFP)-tagged Rab7a (late
endosomal marker, C10588) and LAMP1 (lysosomal marker,
C10596), were obtained from Life Technologies.
Recombinant AAV Production—Recombinant AAV packag-
ing chicken -actin (CBA) promoter-driven firefly luciferase
(fLuc) as well as single-stranded and self-complementary vec-
tors packaging a truncated CBA promoter driving GFP report-
ers were produced in HEK293 cells using the triple plasmid
transfection protocol and purified, and the titers determined as
described earlier (26, 27).
Transduction and Cell Viability Assays—Cells were plated at
a density of 5  104 cells/well in 24-well plates and allowed to
adhere overnight. Unless otherwise indicated, cells were
treated with DMSO vehicle control or EerI for 4 h before trans-
duction with AAV2-CBA-fLuc at 1,000 (vector genomes)
vg/cell. Cells were lysed 24 h after using the luciferase assay
system from Promega (Madison, WI) according to the manufac-
turer’s instructions and read on a Wallac 1420 Victor3 auto-
mated plate reader. Cell viability was assayed using the Cell-
Titer Glo luminescent cell viability assay from Promega
according to the manufacturer’s instructions on the same
instrument. Experiments were all performed in quadruplicate.
For time course studies, EerI was provided at the designated
time points by adding concentrated EerI stock solution in
medium to a final concentration of 10 M.
Cell Surface Binding and Uptake Assays—HeLa cells were
plated at a density of 1  105 cells/well in 24-well plates and
allowed to adhere overnight. Cells were prechilled at 4 °C for 30
min, and then incubated with AAV2 particles at 10,000 vg/cell
for 1 h at 4 °C. Cells were then washed with ice-cold PBS to
remove unbound virions. Cells were then scraped off the plate,
and whole genomic DNA was extracted using a DNeasy kit
(Qiagen). In addition, cells being utilized to monitor viral
uptake were transferred to 37 °C for 1 h, following which cells
were trypsinized andwashed three timeswith PBS to remove all
un-internalized virions. Viral DNA was then extracted using a
DNeasy kit (Qiagen).
Confocal Fluorescence Microscopy—Cells were plated on
slide covers in 24-well plates at a density of 5  104 cells/well
and allowed to adhere overnight. Cells were plated at a density
of 2.5 104 cells/well and infected concurrently with the Bac-
Mam baculovirus encoding for GFP-tagged endosomal
markers (20 copies/cell). Baculovirus was removed from
cells after 24 h, and cells were allowed to recover for an
additional 24 h prior to further studies. Cells were then
treated with EerI 4 h before incubation with AAV2 at 50,000
vg/cell. After 8 h, cells were fixed with 2% paraformaldehyde
for 15 min and then permeabilized with 0.2% Triton X-100
for 5 min. Cells were stained with primary antibody over-
night at 4 °C, and then stained with secondary antibody for
1 h at 37 °C. Cells were then mounted with Prolong Gold
antifade with DAPI (Life Technologies) and imaged using a
Zeiss 710 scanning confocal microscope.
Image Analysis—Quantification of AAV particle colocaliza-
tionwith subcellularmarkerswas carried out using ImageJ soft-
ware with the Colocalization Analysis tools from the Wright
Cell Imaging Facility website. In the case of BacMam 2.0 incu-
bated cells, care was taken to include only cells expressing the
GFP-tagged vesicle markers in the colocalization analysis. Data
are represented as Pearson’s correlation coefficients. Briefly, a
Pearson’s correlation coefficient of 0 represents random local-
ization, whereas a value of 1 represents perfect colocalization.
Therefore, a higher coefficient represents greater colocaliza-
tion of AAV particles with the corresponding subcellular
marker.
Statistical Analysis—All data are expressed as mean with
error bars representing S.E. A two-tailed unpaired student t test
was used for all statistical analysis. p values less than 0.05 were
considered significant. Asterisks are used to indicate p values as
follows: *, p 0.05; **, p 0.01; ***, p 0.005.
Results
Eeyarestatin I Increases AAV Transduction—Small molecule
inhibitors that augment cellular degradation mechanisms have
been used extensively to dissect virus-host interactions (4, 28,
29). We first treated HeLa cells with various small molecules
that modulate the cellular ubiquitin proteasome system and
then incubated the cells with AAV2-CBA-fLuc. Inhibitors of
the proteasome, MG132 and bortezomib, increased transduc-
tion by approximately a log order (Fig. 1A), as reported previ-
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ously (20, 30). Interestingly, PR-619, a pan-deubiquitinase
inhibitor, did not alter transduction, whereas PYR-41, an inhib-
itor of the ubiquitin-activating enzyme UBA1, increased trans-
duction as effectively as proteasome inhibitors (Fig. 1A). We
then investigated a potential role for autophagy in AAV trans-
duction, which has recently been shown to be critical in the
infection pathway of numerous viruses (6–8). However, nei-
ther the autophagy inducer, nicardipine nor the autophagy
inhibitor, spautin-1 altered AAV transduction (Fig. 1B). We
then tested ERAD using two inhibitors, EerI and kifunensine
(Kif). Interestingly, although Kif treatment did not significantly
alter transduction, EerI treatment led to a transduction
increase of approximately a log order (Fig. 1C).
Because EerI has been shown to directly interact with the
AAAATPase valosin-containing protein, also known asVCP/
p97 (31), we utilized three additional VCP inhibitors, ML240,
NMS-873, or DBeQ (N2N4-dibezylquinazoline-2,4-diamine) to
recapitulate these results.However, as shown in Fig. 2A, none of
the VCP inhibitors increased AAV transduction with the
exception of EerI. It should be noted that siRNA-mediated
knockdown of VCP/p97 was accompanied by significant cyto-
toxicity (50%) precluding efforts to directly address the
potential (indirect) role of VCP/p97 in AAV transduction
(data not shown). To confirm whether the increase in trans-
duction efficiency was due to pleiotropic effects of EerI, we
transfected HeLa cells with the pTR-CBA-fLuc packaging
plasmid as control, allowed 48 h for transgene expression,
and then treated the cells with EerI for 24 h. We observed no
change in fLuc expression as a result of EerI treatment (Fig.
2B), confirming that the effect seen exclusively affects AAV
transduction and does not enhance transcription or protein
stability in general.
Next, we investigated the effect of altering EerI concentra-
tion or virus dose on transduction. We observed a dose-de-
pendent increase of AAV transduction at EerI concentra-
tions up to 15 M, after which a decrease in transduction
efficiency was observed due to cytotoxicity (Fig. 2C). Fur-
ther, at an optimal EerI concentration of 10 M, we observed
a uniformly beneficial effect on transduction efficiency in
HeLa cells over a broad range of viral doses ranging from 10
to 10,000 vg/cell (Fig. 2D).
EerI Enhances AAV Transduction Independent of Capsid,
Vector Genome, or Cell Type—We next sought to investigate
whether varying AAV capsid types or cell types affected the
ability of EerI to enhance transduction. We investigated this
possibility by incubating HeLa cells with numerous AAV sero-
types at 1,000 vg/cell. As seen in Fig. 2E, EerI uniformly
increases the transduction of all serotypes tested, although at
varying levels. In addition, transduction was increased in other
human cell types tested, albeit at different optimal EerI concen-
trations based on the toxicity profile (Fig. 2F). Further, we
determined that EerI enhances the intensity of GFP reporter
gene expression mediated by AAV vectors packaging single-
stranded (ss) or self-complementary (sc)GFP reporter cassettes
in a similar fashion (Fig. 2G). Taken together, these data dem-
onstrate that EerI increases transduction regardless of capsid,
second strand synthesis, or cell type.
EerI Redistributes AAV from a Perinuclear Pattern to Large,
Dispersed Vesicles in the Cytoplasm—Given the broad impact
of EerI onAAV transduction, we assessed whether these effects
were preceded by notable changes in the intracellular traffick-
ing ofAAVparticles through confocal fluorescencemicroscopy
studies. Specifically, we pretreated HeLa cells with EerI and
incubated the cells with AAV2 particles, followed by immuno-
fluorescent labeling of AAV capsids and VCP at 2, 4, and 8 h
post-incubation. We observed no significant correlation
between the intracellular patterns of VCP (the apparent target
of EerI discussed later) and AAV capsid immunostaining at 2, 4
or 8 h post-incubation with or without EerI treatment (Fig. 3,
A–C). As seen in higher magnification images (bottom panels),
a steady increase in the perinuclear accumulation of AAV par-
ticles was observed over time. At 8 h post-incubation (Fig. 3C),
we observed that although someAAVparticles remained in the
perinuclear region, a majority of AAV particles redistributed
from the perinuclear space to a large and dispersed punctate
pattern throughout the cytoplasm upon VCP inhibition. This
observation strikingly contrasts with DMSO-treated cells, in
which AAV virions remain concentrated in the perinuclear
region (Fig. 3C, bottom panel).
EerI Redirects AAV Particles to Late Endosomes and
Lysosomes—In an effort to identify the nature of the punctate
structures formed in the cytoplasm upon EerI treatment, we
utilized the BacMam 2.0 system from Life Technologies, which
FIGURE 1. Effect of different chemical inhibitors of cellular degradation
pathways on AAV transduction. A, luciferase reporter expression in HeLa
cells pretreated with vehicle controls or inhibitors of the ubiquitin protea-
some system and transducedwith AAV2-Luc. Effect of proteasome inhibitors
MG132 (10M), bortezomib (500 nM), pan-deubiquitinase inhibitor PR-619 (5
M), or UBE1 inhibitor, PYR-41 (50 M) is shown. RLU, relative light units. B,
HeLa cells pretreatedwith vehicle control or autophagymodulatorsNicardip-
ine (5 M) or Spautin-1 (10 M) transduced with AAV2-Luc. C, HeLa cells pre-
treatedwith vehicle control or ERAD inhibitors EerI (10M) or Kif (1M) trans-
duced with AAV2-Luc vectors.***, p 0.005.
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allowed the delivery of GFP-tagged versions of different endo-
somal markers, specifically Rab7 (late endosome) and LAMP1
(lysosome) using baculoviral expression vectors. In addition,we
utilized an EEA1 antibody to stain for early endosomes. At 8 h
post-incubation, AAV particles did not appear to colocalize
with EEA1 vesicles (data not shown), indicating that AAV is
not associated with early endosomes at this time interval. How-
ever, AAV particles colocalized prominently with Rab7 (Fig.
4A) and more extensively with LAMP1 vesicles in EerI-
treated cells (Fig. 4B). This increased colocalization was further
confirmed by quantitation of fluorescent signal using the
ImageJ software as outlined under “Materials andMethods.” In
particular, we determined the Pearson’s coefficients (Table 1)
forAAVparticle colocalizationwith different subcellularmark-
ers including EEA1 (early endosomes), Rab7a (late endosomes),
LAMP1 (lysosomes), Golgin-97 (Golgi), and STX5 (syntaxin 5).
A statistically significant increase in Pearson’s coefficients was
noted for redistribution of AAVparticles to Rab7 and LAMP1
vesicles.
EerI Influences an Early, Post-entry Trafficking Event during
AAV Transduction—To further understand the effect of EerI
on AAV transduction, we systematically investigated the
impact of EerI treatment on each step of the AAV intracellular
trafficking pathway. First, we assessed whether EerI affects
early steps during transduction, i.e. AAV capsid binding to the
cell surface and endocytic uptake. As seen in Fig. 5, A and B,
EerI treatment does not alter the number of bound virions
attached to the cell surface nor internalized virions at 1 h post-
incubation. Further evidence supporting the notion that EerI
influences a downstream step in the AAV trafficking pathway
was obtained by treating cells at different time intervals before
or after viral incubation. As shown in Fig. 5C, the beneficial
effect of EerI on AAV transduction gradually weakened when
added at later time intervals. Specifically, EerI addition as late as
4 h after incubation with viral particles increased AAV trans-
duction, albeit to a lesser degree when compared with drug
pretreatment. By 8 h post-AAV incubation, the addition of EerI
increased transduction efficiency by less than 1.5-fold. When
FIGURE 2. EerI increases AAV transduction in a serotype-, cell type-, and vector genome-independentmanner. A, luciferase reporter expression in HeLa
cells pretreatedwith vehicle control, 1MML240, 1MNMS-873, 10MDBeQ,or 10MEerIwas transducedwithAAV2-Luc.RLU, relative lightunits.B, luciferase
expression in HeLa cells transfected with the pTR-CBA-Luc plasmid and treated with various concentrations of EerI 48 h post-transfection. C, HeLa cells
pretreatedwith various concentrations of EerI and transducedwithAAV2-Luc (gray bars) or subjected to aCellTiter-Glo assay todetermine cell viability (circles).
D, HeLa cells pretreated with either DMSO control (squares) or EerI (triangles) and transduced with AAV2-Luc at increasing vector genome copies (vg) per cell.
E, HeLa cells were pretreated with DMSO control (gray bars) or EerI (white bars) and transduced with various AAV serotypes packaging the Luc transgene
cassette. F, HepG2, Huh7, and human fibroblasts (hFibroblast) were pretreated with EerI at concentrations individually optimized to limit cytotoxicity (HepG2,
8M; Huh7, 4M; human fibroblasts, 4M) and transducedwith AAV2-CBA-Luc.G, HeLa cells were pretreatedwith DMSO control or EerI and then transduced
with either single-stranded ssAAV2-GFP vectors or self-complementary scAAV2-GFP vectors. Cells were fixed 24 h and imaged using confocal microscopy. *,
p 0.05; **, p 0.01; ***, p 0.005.
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considered together with confocal fluorescence data, these
results suggest that EerI treatment alters the endocytic sorting
of AAV particles after cellular uptake, but prior to nuclear
entry.
EerI and MG132 Enhance AAV Transduction in a Mutually
Exclusive Manner—We next sought to characterize any simi-
larities and/or differences in the effect(s) of proteasome inhib-
itors and EerI on AAV transduction. Confocal microscopy
experiments revealed a stark difference in capsid accumulation
upon treatment with either EerI or MG132. As seen in Fig. 5D,
where EerI treatment results in accumulation in enlarged vesi-
cles, MG132 treatment leads to a more disseminated capsid
accumulation in the perinuclear region. Further, proteasomal
inhibition is thought to directly enhance AAV transduction by
preventing capsid degradation in the cytosol. As a consequence,
enhanced recovery of intact AAV capsids and genomes from
the nuclear fraction has been reported by several groups (20–
23, 32). In the current study, upon EerI treatment, we observed
a striking increase in the number of AAV genomes recovered
after synchronized cellular uptake at later time intervals (Fig.
5E). These results were essentially identical to those obtained
upon proteasomal inhibition with MG132. Specifically, no dif-
ferences in recovered vg were observed at early time intervals
up to 4 h. However, as much as 80–90% of AAV genomes was
recovered at 16–24 h upon treatment with EerI in contrast to
25–35% of AAV genomes obtained from untreated cells. These
data might indicate that EerI treatment indirectly helps protect
AAV genomes from rapid degradation.
The above described results prompted us to further consider
the possibility that EerI might not only affect AAV trafficking,
but also influence AAV capsid degradation in a pleiotropic
manner. To assess this possibility, cells were co-treated with
EerI and MG132, alone or in combination. It is noteworthy to
mention that these studies were optimized to minimize the
combined cytotoxicity arising from dual drug treatment. As
seen in Fig. 5F, EerI enhanced AAV transduction by 4-fold,
whereas MG132 was twice as effective, resulting in an8-fold
increase in transduction. Importantly, combined drug treat-
ment was synergistic and enhanced AAV transduction by
nearly 15-fold. These results demonstrate that cellular degra-
dation pathways can influence AAV infection in distinct ways,
which, when modulated in conjunction, can cumulatively
enhance AAV transduction.
Discussion
EerI is widely viewed as an ERAD inhibitor that is also capa-
ble of augmenting the unfolded protein response (33). In addi-
tion, EerI has been shown to block Sec61-mediated protein
translocation from the cytosol into the ER (34) andwas recently
shown to affect productive ER exit of BK polyomavirus (4).
Intriguingly, EerI has also been reported to interfere with both
retrograde as well as anterograde trafficking of endocytic cargo
FIGURE 3. EerI redirects AAV particles from a perinuclear pattern to a dispersed cytosolic punctate pattern. A–C, confocal micrographs of HeLa cells
pretreated with EerI and transduced with AAV2-Luc at 50,000 vg/cell. Cells were fixed at 2 h (A), 4 h (B), and 8 h (C), immunostained for VCP (green) and AAV2
capsid (magenta) as outlined under “Materials and Methods,” and counterstained with DAPI (blue).White inset boxes indicate areas imaged at higher magni-
fication. Scale bar 20 m. p.i., post incubation.
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(35). Specifically, treatment with this drug not only delayed
the trafficking of Shiga toxin to the perinuclear region and the
Golgi, but also delayed the escape of diphtheria toxin into the
cytosol from acidified vesicles. In the current study, we
observed that EerI treatment redirects the intracellular traffick-
ing of AAV particles from a conventional, Golgi-directed ret-
rograde pathway toward late endosomes and/or lysosomes.
Specifically, a large number ofAAVparticleswere segregated in
large Rab7/LAMP1 vesicles. These observations are sup-
ported in part by earlier studies that reported a dramatic
increase in the size of endosomes upon EerI treatment (36).
Further, these observations are consistent with earlier studies
demonstrating that AAV transport through Rab7 late endo-
somes/lysosomes is highly productive due to their highmotility
and faster retrograde velocities when compared with early/re-
cycling endosomes in neurons (37). Such a scenario is possible
due to the low pH and high protease activity within such vesi-
cles that could more effectively prime the AAV capsid (38) by
exposing the VP1 phospholipase A2 (PLA2) domain (39) and
nuclear localization signals (40).
Another important observation is that EerI treatment
affected AAV trafficking to the microtubule-organizing center
in the perinuclear region. Previous studies have indicated that
AAV transduction efficiency is affected by knockdown of pro-
teins involved in sorting retrograde cargo, such as syntaxin 5,
calnexin, KDEL receptor (KDELR), and other Golgi/ER-associ-
ated proteins (16, 18). In the current study, EerI treatment
appears to decrease the colocalization of AAV particles with
markers such as STX5 and Golgin-97 (Table 1), although these
results were not statistically significant. Nevertheless, our
results suggest that efficient vesicular trafficking can enhance
AAV transduction. This overall approach toward improved
AAV trafficking (depicted in Fig. 6) is further supported by (i)
the increased recovery of vector genome copy numbers from
within cells at time intervals as late as 16–24 h following EerI
treatment, similar to that observed with the proteasomal inhib-
itor, MG132 and (ii) the cumulative effects of EerI and MG132
on AAV transduction.
At themechanistic level, EerI has been shown to directly bind
VCP, an essential component of the ERADmachinery (31, 41).
FIGURE 4.AAVparticles accumulatewithin enlarged Rab7 and Lamp1 vesicles upon treatmentwith EerI. A and B, confocal micrographs of HeLa cells
infectedwith BacMambaculovirus encoding for GFP-Rab7a (A) or GFP-LAMP1 (B). Cells were pretreatedwith DMSO or EerI at 72 h post-plating and incubated
with AAV2-Luc at 50,000 vg/cell. Cells were then fixed at 8 h, immunostained for AAV capsid (magenta), and counterstainedwith DAPI (blue).White inset boxes
indicate areas imaged at higher magnification. Scale bar 20 m.
TABLE 1
Pearson coefficient values for colocalization of subcellular markers
with AAV capsid immunofluorescence (A20monoclonal antibody)
Values are depicted as means S.E. (*, p 0.05: significant; n.s.: not significant).
Subcellular
marker DMSO EerI p value
EEA1 0.198 0.018 0.252 0.040 n.s
Rab7a 0.216 0.019 0.342 0.024 *, p 0.05
LAMP1 0.269 0.036 0.439 0.025 *, p 0.05
Golgin97 0.379 0.025 0.312 0.032 n.s
STX5 0.453 0.009 0.334 0.042 n.s
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However,wenote that attempts tomodulateAAV transduction
by using other small molecule VCP inhibitors (Fig. 2A), using
siRNA-mediated knockdown of VCP/p97, or colocalizing AAV
capsids with VCP/p97 through confocal microscopy or immu-
noprecipitation studies were unsuccessful (data not shown).
These studies are also particularly challenging due to overt tox-
icity displayed during RNAi-mediated knockdown of VCP as
well as overexpression of WT/dominant negative forms of
VCP. Thus, it is important to consider the pleotropic effects of
chemical inhibitors such as EerI in such studies. This aspect is
also consistent with earlier studies, where EerI has been shown
to augment cellular processes separate fromERAD (34–36, 42).
Thus, the exact molecular mechanism(s) that are implicated in
the current study remain to be determined.
A key question is whether such studies have the potential for
translational impact in recombinant AAV vector-mediated
gene therapy. In this regard, numerous chemical inhibitors of
VCP, including EerI, are currently being evaluated for their
potential as chemotherapeutics (43, 44). However, similar to
proteasome inhibitors such as bortezomib, the effective dose
FIGURE 5. EerI andMG132 increaseAAV transduction throughdistinct, yet cumulativemechanisms.A, cell surface binding of AAVparticles incubated on
HeLa cells thatwere pretreatedwithDMSOor EerI. Viral particleswere incubated on cells at 4 °C for 1 h, followingwhich cellswerewashed to removeunbound
virus and cell surface-associated vector genomeDNAwas quantified by quantitative PCR. RLU, relative light units. B, HeLa cells incubatedwith AAV particles at
4 °C for 1 h were washed to remove unbound virions and then shifted to 37 °C for 1 h to allow cellular uptake. Cells were then treated with trypsin to remove
surface-bound virions, and internalized virions were quantitated by quantitative PCR. C, luciferase expression in HeLa cells treated with DMSO control or EerI
at various time intervals prior to transductionwith AAV2-Luc vectors.D, confocalmicrographs of HeLa cells pretreatedwith EerI orMG132 and incubatedwith
AAV particles at 50,000 vg/cell. Cells were fixed at 8 h, immunostained for AAV capsids (magenta), and counterstained with DAPI (blue). Scale bar 20 m. E,
recovery of internalized vector genome-containing particles at different time intervals fromHeLa cells pretreated with DMSO, EerI, or MG132 and transduced
with AAV2-Luc as described above. F, luciferase expression in HeLa cells pretreated with DMSO control, EerI, MG132, or EerI and MG132 in combination and
transducedwithAAV2-Luc. At 4 hpost-incubation, thedrugs and viruswere removed and replacedwith freshprewarmedmedium. *,p 0.05; **,p 0.01; ***,
p 0.005.
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and toxicity of such agents will need to be determined in pre-
clinical animal models as well as the clinic prior to potential
applications in the gene therapy setting. Nevertheless, our
study constitutes an important step forward in understanding
the interplay between different cellular degradation pathways
that influence AAV trafficking and highlight potential strate-
gies to modulate the same.
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